BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Conor Medsystems, Inc. To Present COSTAR II Data At EuroPCR


2/23/2007 2:49:05 PM

MENLO PARK, Calif., Feb. 23 /PRNewswire/ -- Conor Medsystems, Inc. today announced it plans to present the results for its COSTAR II U.S. pivotal clinical trial at the EuroPCR meeting in Barcelona in May.

"The last patient was followed-up in February 2007, and we expect the independent clinical research organization to commence the data analysis in March, providing sufficient time for presentation at the upcoming EuroPCR meeting," said Michael Boennighausen, General Manager, Conor Medsystems. "We look forward to the opportunity to present these data in May."

The COSTAR II clinical trial is a randomized, single-blind, non-inferiority study comparing Conor Medsystems' CoStar(R) cobalt chromium paclitaxel-eluting stent with Boston Scientific's Taxus(R) Express2 drug- eluting stent in the treatment of de novo lesions in patients with single or multi-vessel coronary artery disease. It includes 1,700 patients from more than 70 clinical sites.

Johnson & Johnson acquired Conor Medsystems in February of this year.

About Conor Medsystems

Conor Medsystems develops innovative controlled vascular drug delivery technologies, and has primarily focused on the development of drug-eluting stents to treat coronary artery disease. For further information on Conor Medsystems and controlled vascular delivery, visit http://www.conormed.com.

The CoStar(R) stent is not available for sale in the U.S. The CoStar(R) stent is an investigational device limited by law to investigational use in the U.S.

Conor Medsystems, Inc.

CONTACT: Media, Christopher Allman, office, +1-786-313-2303, mobile,+1-305-586-6024, or Analysts, Stan Panasewicz, Johnson & Johnson, office,+1-732-524-2524



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES